Summaries for Patients |

Validity of Models for Predicting BRCA1 and BRCA2 Mutations FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Validity of Models for Predicting BRCA1 and BRCA2 Mutations.” It is in the 2 October 2007 issue of Annals of Internal Medicine (volume 147, pages 441-450). The authors are G. Parmigiani, S. Chen, E.S. Iversen Jr., T.M. Friebel, D.M. Finkelstein, H. Anton-Culver, A. Ziogas, B.L. Weber, A. Eisen, K.E. Malone, J.R. Daling, L. Hsu, E.A. Ostrander, L.E. Peterson, J.M. Schildkraut, C. Isaacs, C. Corio, L. Leondaridis, G. Tomlinson, C.I. Amos, L.C. Strong, D.A. Berry, J.N. Weitzel, S. Sand, D. Dutson, R. Kerber, B.N. Peshkin, and D.M. Euhus.

Ann Intern Med. 2007;147(7):I-38. doi:10.7326/0003-4819-147-7-200710020-00001
Text Size: A A A

What is the problem and what is known about it so far?

Two genes, BRCA1 and BRCA2, occur infrequently in the population but are relatively common in women of Ashkenazi Jewish ancestry and in women with a strong family history of breast cancer. When a woman has defects in 1 of these genes, she is very likely to have breast (or ovarian) cancer during her lifetime. Many women are worried that they have mutations of these genes, and they seek advice about whether to be tested for it. Because the mutation test is expensive, counselors estimate the probability that a woman has the BRCA1/BRCA2 mutations. One way to estimate the probability of the mutation is to ask questions and then use the answers to make an educated guess. The accuracy of the guess will depend on the skill and experience of the counselor. However, better ways exist. They are called prediction models. They use knowledge about the exact relationship between a woman's history—including how many family members had breast cancer—and defects in the BRCA1/BRCA2 genes. They obtain this knowledge by asking women about their medical history, testing each woman for mutations of the BRCA1/BRCA2 genes, and doing statistical tests to identify which parts of the history are most strongly related to having the mutations. Using these models, anyone—a counselor or a patient—could calculate a woman's probability of having BRCA1/BRCA2 mutation. Many prediction models exist.

Why did the researchers do this particular study?

To compare 7 prediction models to determine whether any was clearly better in detecting a BRCA1/BRCA2 gene mutation.

Who was studied?

3342 families—nearly all women—who were patients in 9 cancer counseling centers. Each person had been tested for the BRCA1/BRCA2 gene mutation, and 17% had positive results on the genetic test.

How was the study done?

The researchers applied the 7 prediction models to every person and calculated the probability that the person had a mutation of the BRCA1/BRCA2 gene. Because the researchers knew the results of the tests for BRCA1/BRCA2 mutation, they could measure the accuracy of each model in people from 9 cancer practices.

What did the researchers find?

The study had 3 main findings. First, using 7 different prediction models in 1 person often gave 7 different numbers to represent that person's probability of having a BRCA1/BRCA2 mutation. In other words, the models often didn't agree very well. Second, the models were similarly good at discriminating between persons with a BRCA1/BRCA2 mutation and persons without a BRCA1/BRCA2 gene mutation. Third, the models can make mistakes.

What were the limitations of the study?

One prediction model calculated a number that is not a probability, which makes it harder to compare it with those that do estimate a probability.

What are the implications of the study?

Although the prediction models can usually distinguish between someone with a BRCA1/BRCA2 mutation and someone without a mutation, they can make mistakes. This means that patients should not rely entirely on the predicted probability when deciding whether to have mutation testing. Patients should discuss other factors that should be taken into consideration with their doctors.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.